- Volume 15 Issue 19
DOI QR Code
Systematic Analysis of Pemetrexed-based Chemoradiotherapy for Patients with Locally Advanced or Metastatic Esophageal Cancer
- Tian, Guang-Yu (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
- Miu, Min (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
- Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
- Published : 2014.10.23
Purpose: This systematic analysis was conducted to evaluate the efficacy and safety of pemetrexed-based chemoradiotherapy in treating patients with locally advanced or metastatic esophageal cancer. Methods: Clinical studies evaluating the efficacy and safety of pemetrexed based regimens on response and safety for relevant patients were identified using a predefined search strategy. Pooled response rates (RRs) were calculated. Results: For pemetrexed-based regimens, 4 clinical studies including 47 patients with locally advanced or metastatic esophageal cancer were considered eligible for inclusion. Systematic analysis showed that, in all patients, the pooled RR was 51% (24/47). Major adverse effects of grade III/IV were esophagitis, neutropenia, thrombocytopenia, anemia anorexia, fatigue, diarrhea, dysphagia and vomiting. No treatment related death occurred with pemetrexed-based treatment. Conclusion: This systematic analysis suggests that pemetrexed based radiotherapy is associated with reasonable activity and good tolerability in treating patients with locally advanced or metastatic esophageal cancer.
Metastatic esophageal cancer;pemetrexed-based chemoradiotherapy;efficacy;tolerability
- Ajani JA, Ilson DH, Daugherty K, et al (1994). Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst, 86, 1086-91. https://doi.org/10.1093/jnci/86.14.1086
- Holmes FA, Valero V, Buzdar AU (1998). Final results: randomized phase III trial of paclitaxel by 3-hour versus 96-hour infusion in patients with metastatic breast cancer: the long and the short of it. Proc Am Soc Clin Oncol, 17, 110a (Abstr 426).
- Bhatt RS, Merchan J, Parker R, et al (2010). A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer, 116, 1751-6. https://doi.org/10.1002/cncr.24902
- Bucci MK, Rosenthal DI, Hershock D, et al (2004). Final report of a pilot trial of accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel for locally advanced head and neck cancer. Am J Clin Oncol, 27, 595-602. https://doi.org/10.1097/01.coc.0000135738.85334.ed
- Herscher LL, Cook J (1999). Taxanes as radiosensitizers for head and neck cancer. Curr Opin Oncol, 11, 183-6. https://doi.org/10.1097/00001622-199905000-00008
- Jatoi A, Soori G, Foster NR, et al (2010). Phase II study of preoperative pemetrexed, carboplatin, and radiation followed by surgery for locally advanced esophageal cancer and gastroesophageal junction tumors. J Thorac Oncol, 5, 1994-8. https://doi.org/10.1097/JTO.0b013e3181fb5c3e
- Katipamula R, Jatoi A, Foster NR, et al (2008). Pemetrexed, Carboplatin, and Concomitant Radiation followed by Surgery for Locally Advanced Esophageal Cancer: Results of a Planned Interim Toxicity Analysis of North Central Cancer Treatment Group Study N044E. Clin Med Oncol, 2, 223-5.
- Kelsey CR, Chino JP, Willett CG, et al (2007). Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. Int J Radiat Oncol Biol Phys, 69, 770-6. https://doi.org/10.1016/j.ijrobp.2007.03.035
- Langer CJ, Harris J, Horwitz EM, et al (2007). Phase II study of low-dose paclitaxel and cisplatin in combination with splitcourse concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol, 25, 4800-5. https://doi.org/10.1200/JCO.2006.07.9194
- Mirinezhad SK, Somi MH, Jangjoo AG, et al (2012). Survival rate and prognostic factors of esophageal cancer in east Azerbaijan province, North-west of Iran. Asian Pac J Cancer Prev, 13, 3451-4. https://doi.org/10.7314/APJCP.2012.13.7.3451
- Li BS, Gong HY, Huang W, et al (2011). Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and pemetrexed, cisplatin for locally advanced esophageal squamous cell carcinoma. Dis Esophagus, b, 251-7.
- Liu JL, Zhou LL, Cai MH, et al (2009). Observation on the short-term effect of nedaplatin plus tegafur in the treatment of advanced esophageal carcinoma. J Pract Oncol, 24, 515-6.
- Jiang C, Liao FX, Rong YM, et al (2014). Efficacy of taxanebased regimens in a first-line setting for recurrent and/or metastatic Chinese patients with esophageal cancer. Asian Pac J Cancer Prev, 15, 5493-8. https://doi.org/10.7314/APJCP.2014.15.13.5493
- Orditura M, Galizia G, Napolitano V, et al (2010). Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study. Cancer Invest, 28, 820-7. https://doi.org/10.3109/07357901003630926
- Polee MB, Eskens FA, van der Burg ME, et al (2002). Phase II study of biweeklyadministration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer, 86, 669-73. https://doi.org/10.1038/sj.bjc.6600166
- Safran H, Dipetrillo T, Akerman P, et al (2007). Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys, 67, 405-9. https://doi.org/10.1016/j.ijrobp.2006.08.076
- Seidman AD, Hochhauser D, Gollub M, et al (1996). Ninetysix hour paclitaxel infusion after progression during taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol, 14, 1877-84.
- Tsuya A, Kaneda K, Okano S, et al (1968). Effects of 5-FU (5-fluorouracil) in 4.3MeV Linac x-ray treatment of advanced cancer. Gan No Rinsho, 14, 340-52.
- Seiwert TY, Connell PP, Mauer AM, et al (2007). A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res, 13, 515-22. https://doi.org/10.1158/1078-0432.CCR-06-1058
- Shade RJ, Pisters KM, Huber MH, et al (1998-1999). Phase I study of paclitaxel administered by ten-day continuous infusion. Invest New Drugs, 16, 237-43.
- Tang WR1, Fang JY, Wu KS, et al (2014). Epidemiological characteristics and prediction of esophageal cancer mortality in China from 1991 to 2012. Asian Pac J Cancer Prev, 15, 6929-34. https://doi.org/10.7314/APJCP.2014.15.16.6929
- Wang J, Yu JM, Jing SW, et al (2014). Relationship between EGFR over-expression and clinicopathologic characteristics in squamous cell carcinoma of the esophagus, a metaanalysis. Asian Pac J Cancer Prev, 15, 5889-93. https://doi.org/10.7314/APJCP.2014.15.14.5889
- Wang T, Zhang SF, Wang L (2010). A 24-hour continuous infusion of paclitaxel in the treatment of advanced esophageal cancer. Nat Med J China, 90, 1986-8.
- Wei GL, Huang XE, Huo JG, et al (2013). Phase II study on pemetrexed-based chemotherapy in treating patients with metastatic gastric cancer not responding to prior palliative chemotherapy. Asian Pac J Cancer Prev, 14, 2703-6. https://doi.org/10.7314/APJCP.2013.14.5.2703
- West HL, Crowley JJ, Vance RB, et al (2005). Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714) : a Southwest Oncology Group study. Ann Oncol, 16, 1076-80. https://doi.org/10.1093/annonc/mdi215
- Wong R, Malthaner R (2003). Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev, 1, CD002092.
- Clinical Study on Safety and Efficacy of JiSaiXin (Recombinant Human Granulocyte Colony Stimulating Factor Injection Manufactured in China) for Chinese Undergoing Chemotherapy vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.299
- Pathologic Response During Chemo-radiotherapy and Variation of Serum VEGF Levels Could Predict Effects of Chemo-Radiotherapy in Patients with Esophageal Cancer vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.1111
- Clinical Investigation in Effect of Riboflavin Sodium Phosphate on Prevention and Treatment for Patients with Radiotherapy Related Esophagitis vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1525
- Clinical Application of Serum Tumor Abnormal Protein (TAP) in Colorectal Cancer Patients vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3425
- Pemetrexed in Treating Patients with Metastatic Bladder Cancer vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3839
- Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma vol.76, pp.4, 2015, https://doi.org/10.1007/s00280-015-2854-0
- Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.413
- A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.485